5 recruiting, 2 completed, 2 terminated, 1 active not recruiting. 12 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Recruiting 5, Completed 2, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 4 | Recruiting 3, Unknown 1 |
Follow Heart Failure With Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure With Reduced Ejection Fraction trials Research Report on Heart Failure With Reduced Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure Pulmonary Vein Isolation, Pharmacological Rate Control - Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation (AF) | Phase 3 | Not yet recruiting | University of British Columbia | 1050 | 2026-11-01 | 2026-10-14 |
| HFrEF Polypill in Sri Lanka RCT Usual Care, HFrEF Polypill - Heart Failure With Reduced Ejection Fraction | Phase 3 | Recruiting | Washington University School of Medicine | 1672 | 2026-08-17 | 2026-10-22 |
| Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension Midodrine Oral Tablet - Heart Failure With Reduced Ejection Fraction, Hypotension | Phase 2 / Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 56 | 2026-08-07 | 2026-09-08 |
| Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy GDMT - Heart Failure With Reduced Ejection Fraction, Heart Rhythm Disorder | Phase 2 / Phase 3 | Recruiting | Herlev and Gentofte Hospital | 348 | 2025-01-09 | 2026-02-23 |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Omecamtiv Mecarbil (OM), Placebo - Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 3 | Recruiting | Cytokinetics | 1800 | 2024-12-19 | 2026-11-04 |
| Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure Semaglutide Injectable Product, Calorie-restricted diet - Heart Failure With Reduced Ejection Fraction, Obesity | Phase 2 / Phase 3 | Recruiting | Jens D Hove, MD,PHD | 100 | 2024-04-30 | 2026-06-23 |
| A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure Pulmonary arterial denervation, Guideline-directed medical therapy (GDMT) for heart failure - Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction | Phase 3 | Active not recruiting | Pulnovo Medical (Wuxi) Co., Ltd. | 264 | 2023-08-14 | 2026-07-21 |
| " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Empagliflozin 10 MG OD - Congenital Heart Disease, Heart Failure | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 160 | 2023-02-06 | 2022-11-02 |
| Lokelma for RAAS Maximisation in CKD & Heart Failure. Lokelma Oral Product - Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction | Phase 3 | Completed | St George's, University of London | 112 | 2022-01-19 | 2026-04-27 |
| Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study Ertugliflozin 5 mg, Placebo 5mg - Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction | Phase 3 | Terminated | Medical University of Graz | 55 | 2021-06-24 | 2025-06-03 |
| Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure Omecamtiv Mecarbil, Placebo - Heart Failure With Reduced Ejection Fraction | Phase 3 | Completed | Cytokinetics | 276 | 2019-04-09 | 2023-03-07 |
| This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure LCZ696 200 mg BID, Enalapril 10 mg BID - Heart Failure With Reduced Ejection Fraction | Phase 3 | Terminated | Novartis Pharmaceuticals | 8442 | 2009-12-01 | 2016-08-15 |
Heart Failure (7) · Acute Kidney Injury (1) · Atrial Fibrillation (1) · Cardiomyopathies (1) · Cardiovascular Diseases (1) · Heart Defects, Congenital (1) · Hyperkalemia (1) · Hypertension (1) · Hypertension, Pulmonary (1) · Hypotension (1) · Obesity (1) · Pseudohypoaldosteronism (1) · Renal Insufficiency, Chronic (1) · Tachycardia, Ventricular (1) · Vascular Diseases (1)
Heart Diseases (7) · Cardiovascular Diseases (6) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (3) · Arrhythmias, Cardiac (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Nutritional and Metabolic Diseases (2) · Body Weight (1) · Body Weight Changes (1) · Cardiac Conduction System Disease (1) · Cardiovascular Abnormalities (1) · Chronic Disease (1) · Congenital Abnormalities (1) · Disease Attributes (1) · Female Urogenital Diseases (1)
BID protein, human (2) · omecamtiv mecarbil (2) · sacubitril and valsartan sodium hydrate drug combination (2) · Caloric Restriction (1) · Enalapril (1) · Midodrine (1) · Valsartan (1) · empagliflozin (1) · ertugliflozin (1) · sacubitril (1)
Cytokinetics (2) · Herlev and Gentofte Hospital (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Jens D Hove, MD,PHD (1) · Medical University of Graz (1) · Novartis Pharmaceuticals (1) · Ottawa Heart Institute Research Corporation (1) · Pulnovo Medical (Wuxi) Co., Ltd. (1) · St George's, University of London (1) · University of British Columbia (1) · Washington University School of Medicine (1)
Canada (4) · China (3) · Denmark (3) · France (3) · Germany (3) · Italy (3) · Poland (3) · United Kingdom (3) · United States (3) · Hungary (2) · Mexico (2) · Netherlands (2) · Spain (2) · Sweden (2) · Argentina (1)
Carlos Guizar-Sanchez, MD (1) · Debasish Banerjee, MD FRCP (1) · Dirk von Lewinski, Assoc-Prof. (1) · Edgar Garcia-Cruz, MD (1) · Emil Wolsk, MD (1) · Gian Jimenez-Rodriguez, MD (1) · Ian Paterson, MD (1) · Jens D Hove (1) · Montserrat Villalobos-Pedroza, MD (1) · Yaling Han (1)
PMID 23563576, PMID 25176015, PMID 25403646, PMID 25416329, PMID 26022006, PMID 26231885, PMID 26280447, PMID 26541915, PMID 26754626, PMID 26915374, PMID 27143684, PMID 27296397, PMID 27354044, PMID 27395349, PMID 27618854, PMID 27842179, PMID 27895026, PMID 27908347, PMID 28784687, PMID 29018174, PMID 29141857, PMID 29617523, PMID 29661699, PMID 29748349, PMID 30204280, PMID 30520545, PMID 30784673, PMID 30846338, PMID 31078482, PMID 31302043, PMID 31510768, PMID 31736342, PMID 31813280, PMID 31849164, PMID 32720404, PMID 32865377, PMID 33186500, PMID 33447845, PMID 33522249, PMID 33832352, PMID 33888245, PMID 34101002, PMID 34327735, PMID 35045327, PMID 35236099, PMID 35603665, PMID 35852527, PMID 36477809, PMID 36943907, PMID 37051752
2009 (1), 2018 (1), 2023 (1)